<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156895</url>
  </required_header>
  <id_info>
    <org_study_id>A4061075</org_study_id>
    <nct_id>NCT02156895</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea</brief_title>
  <official_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to monitor the usage of INLYTA® in real practice, including
      the adverse events associated with INLYTA®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators can choose any patient who is within the scope of I/E criteria
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and possible causality will be monitored in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor response based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) within limited follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients who are using Axitinib</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>based on Axitinib approval</description>
    <arm_group_label>Patients who are using Axitinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korea who has a disease for which Axitinib is indicated
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

        Exclusion Criteria:

          -  Any patient who does not agree that Pfizer or companies working on behalf of Pfizer
             can use his/her information.

          -  Patients with hypersensitivity to axitinib or to any other component of INLYTA® .

          -  Patients under 18.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&amp;StudyName=Post%20Marketing%20Surveillance%20Study%20to%20Observe%20Safety%20and%20Efficacy%20of%20Inlyta%20in%20South%20Korea</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean PMS of Axitinib</keyword>
  <keyword>Metastatic RCC ; 2nd line only</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
